ALK and neoplasm: A variety of ALK inhibitors are available, including crizotinib, ceritinib, lorlatinib, alectinib, entrectinib and brigatinib, that can downregulate the STAT3 pathway in patients with ALK-positive pcALCL, thereby causing apoptosis among tumour cells [78].